EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MAP ‐2: CD55 chimeric construct effectively modulates complement activation

Lydia González-Del-Barrio, Laura Pérez-Alós iD, Leon Cyranka iD, Anne Rosbjerg iD, Simon Nagy, Zoltán Prohászka iD, Peter Garred iD, Rafael Bayarri-Olmos iD

The FASEB Journal · 2023-11 · 37 (11)

DOI: 10.1096/fj.202300571r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 12.10.2023. Verfasst von Lydia González-Del-Barrio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmar…. Hauptthemen laut MEDLINE: Complement Activation, Complement System Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system is a complex, tightly regulated protein cascade involved in pathogen defense and the pathogenesis of several diseases. Thus, the development of complement modulators has risen as a potential treatment for complement‐driven inflammatory pathologies. The enzymatically inactive MAP‐2 has been reported to inhibit the lectin pathway by competing with its homologous serine protease MASP‐2. The membrane‐bound complement inhibitor CD55 acts on the C3/C5 convertase level. Here, we fused MAP‐2 to the four N‐terminal domains of CD55 generating a targeted chimeric inhibitor to modulate complement activation at two different levels of the complement cascade. Its biological properties were compared in vitro with the parent molecules. While MAP‐2 and CD55 alone showed a minor inhibition of the three complement pathways when co‐incubated with serum (IC50 MAP‐2+CD55 1‐4 = 60.98, 36.10, and 97.01 nM on the classical, lectin, and alternative pathways, respectively), MAP‐2:CD55 1‐4 demonstrated a potent inhibitory activity (IC50 MAP‐2:CD55 1‐4 = 2.94, 1.76, and 12.86 nM, respectively). This inhibitory activity was substantially enhanced when pre‐complexes were formed with the lectin pathway recognition molecule mannose‐binding lectin (IC50 MAP‐2:CD55 1‐4 = 0.14 nM). MAP‐2:CD55 1‐4 was also effective at protecting sensitized sheep erythrocytes in a classical hemolytic assay (CH50 = 13.35 nM). Finally, the chimeric inhibitor reduced neutrophil activation in full blood after stimulation with Aspergillus fumigatus conidia, as well as phagocytosis of conidia by isolated activated neutrophils. Our results demonstrate that MAP‐2:CD55 1‐4 is a potent complement inhibitor reinforcing the idea that engineered fusion proteins are a promising design strategy for identifying and developing drug candidates to treat complement‐mediated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement ActivationComplement System ProteinsAnimalsSheepCD55 AntigensLectinsTranscription FactorsComplement Inactivating AgentsMannose-Binding Protein-Associated Serine Proteases

Stichwörter der Autor:innen

CD55MAP-2complement inhibitioncomplement regulationlectin pathway

Substanzen

Complement System ProteinsCD55 AntigensLectinsTranscription FactorsComplement Inactivating AgentsMannose-Binding Protein-Associated Serine Proteases

Autor:innen und Institutionen

  • Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Recombinant Protein and Antibody Unit, Copenhagen University Hospital, Rigshospitalet, Denmark.
  • Research Laboratory, Department of Internal Medicine and Hematology, and MTA-SE Research Group of Immunology and Hematology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Laura Pérez-Alós, Leon Cyranka, Anne Rosbjerg, Zoltán Prohászka, Peter Garred, Rafael Bayarri-Olmos

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

González-Del-Barrio, L., Pérez-Alós, L., Cyranka, L., Rosbjerg, A., Nagy, S., Prohászka, Z., Garred, P., & Bayarri-Olmos, R. (2023). MAP ‐2: CD55 chimeric construct effectively modulates complement activation. The FASEB Journal, 37(11). https://doi.org/10.1096/fj.202300571r

Vancouver

González-Del-Barrio L, Pérez-Alós L, Cyranka L, Rosbjerg A, Nagy S, Prohászka Z, et al. MAP ‐2: CD55 chimeric construct effectively modulates complement activation. The FASEB Journal. 2023;37(11). doi:10.1096/fj.202300571r

BibTeX
@article{GonzlezDelBarrio2023,
  author = {González-Del-Barrio, Lydia and Pérez-Alós, Laura and Cyranka, Leon and Rosbjerg, Anne and Nagy, Simon and Prohászka, Zoltán and Garred, Peter and Bayarri-Olmos, Rafael},
  title = {MAP ‐2: CD55 chimeric construct effectively modulates complement activation},
  journal = {The FASEB Journal},
  year = {2023},
  volume = {37},
  number = {11},
  doi = {10.1096/fj.202300571r}
}
Kostenlos starten →